BML, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,908 JPY | -0.14% |
|
-1.76% | -3.07% |
| Sales 2024 * | 138B 889M | Sales 2025 * | 141B 910M | Capitalization | 114B 733M |
|---|---|---|---|---|---|
| Net income 2024 * | 6.37B 41.09M | Net income 2025 * | 6.67B 43.03M | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | 78.11B 504M | Net cash position 2025 * | 72.37B 467M | EV / Sales 2025 * | 0.29 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.8
x | Employees | 4,415 |
| Yield 2024 * |
2.75% | Yield 2025 * |
2.86% | Free-Float | 56.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.14% | ||
| 1 week | -1.76% | ||
| Current month | -0.03% | ||
| 1 month | -3.23% | ||
| 3 months | +0.41% | ||
| 6 months | +2.36% | ||
| Current year | -3.07% |
1 week
2 879.00
2 997.00
1 month
2 879.003 125.00
Current year
2 613.003 125.00
1 year
2 594.003 250.00
3 years
2 594.004 985.00
5 years
2 307.004 985.00
10 years
1 360.504 985.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 94-05-31 |
Yuji Yamashita
CTO | Chief Tech/Sci/R&D Officer | 58 | 88-10-31 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 05-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 94-05-31 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 05-05-31 |
Tatsuharu Arai
BRD | Director/Board Member | 67 | 21-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 23 M€ | +2.70% | - | |
| 0.10% | 19 M€ | +4.43% | ||
| 0.02% | 73 M€ | +11.61% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2,908 | -0.14% | 38 100 |
| 24-04-23 | 2,912 | -1.42% | 40,200 |
| 24-04-22 | 2,954 | +1.79% | 42,200 |
| 24-04-19 | 2,902 | -1.49% | 67,900 |
| 24-04-18 | 2,946 | -0.47% | 32,800 |
Delayed Quote Japan Exchange, April 24, 2024 at 02:00 am EDT
More quotes
BML, INC. is mainly engaged in the clinical testing as well as related business. The Testing segment engages in the commissioned work of clinical testing. The Medical Information Systems segment is engaged in the manufacturing and sales of system equipment for medical institutions, as well as provision of medical information service.
Calendar
2024-05-09
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2,912
JPY
Average target price
3,033
JPY
Spread / Average Target
+4.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.07% | 733M | |
| -16.65% | 8.36B | |
| +40.44% | 3.6B | |
| -29.20% | 2.87B | |
| -7.18% | 2.47B | |
| -9.65% | 2.24B | |
| -18.40% | 1.56B | |
| -39.52% | 1.23B | |
| +9.05% | 1.13B | |
| -18.10% | 1.04B |
- Stock Market
- Equities
- 4694 Stock
